Injectable Medication | Page 6 of 10

New Type 2 Diabetes Drug, Bydureon, Shows Positive Effect on A1c and Weight

Amylin, Eli Lilly and Alkermes, announced results from long-term extensions of the DURATION-1 and 3 studies evaluating Bydureon (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes. The studies will be presented at the...

Lilly and Amylin Type 2 Diabetes Drug, Bydureon, Approved for Marketing in Europe

The European Commission has granted marketing authorization to Eli Lilly, Amylin Pharmaceuticals and Alkermes' type 2 diabetes drug Bydureon (exenatide extended-release for injectable suspension). Bydureon is a glucagon-like peptide-1 (GLP-1) receptor agonist, and is the first once-weekly treatment for type 2 diabetes. It delivers glycemic control in a single weekly dose and is indicated for the treatment of type 2 diabetes in adult patients...

Novo Nordisk Issues Letter Reminding Healthcare Professionals of Victoza Risks

Novo Nordisk issued a letter reminding healthcare professionals of important safety information about the type 2 diabetes drug Victoza (liraglutide [rDNA origin]). The letter was issued because a recent assessment of healthcare providers showed that some primary care providers are not fully aware of the serious risks associated with the use of Victoza...

Sanofi Releases More Results from Type 2 Diabetes Drug Lyxumia (lixisenatide) Study

Sanofi has released additional positive results from the global GetGoal Phase III development program with Lyxumia (lixisenatide) for the treatment of type 2 diabetes. Lyxumia (lixisenatide), a once-daily GLP-1 receptor agonist, was invented by Zealand Pharma and global rights are with Sanofi...

Amylin Files Lawsuit Against Eli Lilly Over Type 2 Diabetes Drug

Amylin Pharmaceuticals announced that it has filed a lawsuit against Eli Lilly. Amylin alleges Lilly is engaging in anticompetitive activity and breaching its strategic alliance agreements to maximize commercialization of exenatide currently marketed as BYETTA® (exenatide) injection...

JDRF and Amylin Team Up to Investigate Hormone Combination for Diabetes Treatment

The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals have entered into a research collaboration agreement to provide financial support for a series of clinical studies to investigate the feasibility of mixing pramlintide...

Bydureon Receives Positive Opinion From The European Medicines Agency

Eli Lilly and Company, Amylin Pharmaceuticals and Alkermes announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of Bydureon for injection in the European Union for the treatment of type 2 diabetes in combination with...

Victoza More Effective Than Competitors New Study Shows

A new meta study presented by Novo Nordisk at the 20th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists (AACE) shows that regardless of baseline A1C, once-daily Victoza (liraglutide [rDNA origin] injection) 1.8 mg consistently helped more patients achieve blood sugar control than...

Sanofi-aventis Announces Positive Results for Lixisenatide

Sanofi-aventis announced today that lixisenatide, a once-daily GLP-1 receptor agonist under development for people with type 2 diabetes, achieved its primary efficacy objective of significant HbA1c reduction and improved glycemic control from...

Victoza Approved for Treatment of Type 2 Diabetes in China

The Chinese State Food and Drug Administration (SFDA) has approved Victoza for the treatment of type 2 diabetes. Diabetes is a rapidly growing disease in China, and Victoza offers a unique treatment option by effectively reducing HbA1c and weight with a low risk of hypoglycemia in people with type 2 diabetes inadequately controlled by oral anti-diabetic agents...

Category: Injectable Medication